Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AmpliPhi Signs Exclusive License With University of Leicester, UK

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
Collaboration and license agreement to develop bacteriophage therapies targeting Clostridium difficile.

AmpliPhi BioSciences Corporation has announced that it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile (C. difficile), a serious gastrointestinal infection for which new treatments are urgently required.

Under the terms of the agreements, AmpliPhi will fund Dr Martha Clokie’s team at the University of Leicester to progress non-clinical studies of bacteriophage products as an alternative to treating antibiotic resistant infections caused by C. difficile bacteria.

Evaluations of the efficacy of bacteriophage therapy will be carried out at the University of Glasgow, UK, in the laboratory of Dr Gill Douce, under a three-way collaborative project between AmpliPhi, Leicester and Glasgow.

C. difficile infection is widely accepted to be the leading cause of hospital-acquired (or nosocomial) infection-related morbidity and mortality, outpacing both antibiotic-resistant staphylococcus (MRSA) and enterococcus (VRE).

Community-acquired cases also appear to be increasing in incidence. Figures released by the US Center for Disease Control in its September 2013 report on antibiotic resistance, classed C. difficile as an urgent threat, causing 250,000 infections in the US every year and costing $1billion a year in excess medical costs.

The team at the University of Leicester has discovered phages that have been shown to be effective against clinically-relevant strains of C. difficile isolated from around the world.

AmpliPhi will license the patents, materials and know-how related to these discoveries from the University of Leicester and, rights, title and interest to any future intellectual property developed under this collaboration will belong to AmpliPhi.

Furthermore, AmpliPhi will have exclusive rights to certain background intellectual property of the University of Leicester, for which AmpliPhi will make milestone payments based on product development and pay royalties based on product sales.

Philip J. Young, CEO of AmpliPhi said “C. difficile causes at least 14,000 deaths a year in the US alone. We are very excited to be working with both the UK based teams to continue the development of innovative bacteriophage therapies. The progress has been impressive to date. We believe that this is the only phage based development program for this critical indication. Developing a treatment for C. difficile is in keeping with our global strategy to develop bacteriophage therapies for the rapidly escalating problem of antibiotic resistance.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AmpliPhi Announces the Appointment of Baxter Phillips
Industry leader brings broad strategic and licensing experience in development and commercial stage biopharmaceutical companies.
Thursday, November 14, 2013
AmpliPhi Establishes Collaboration with Intrexon
Combined expertise to create new generation of bacteriophage-based therapeutics for antibiotic resistant infections.
Thursday, April 18, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!